| Dr Chad E Paxson, DO | |
|
725 Glenwood Dr, Suite E-500, Chattanooga, TN 37404-1163 | |
| (423) 495-2635 | |
| (423) 495-2638 |
| Full Name | Dr Chad E Paxson |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 20 Years |
| Location | 725 Glenwood Dr, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366562894 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 2605 (Tennessee) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 2605 (Tennessee) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Chi Memorial Hospital- Georgia | Fort oglethorpe, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Health Partners Foundation, Inc | 8022919570 | 303 |
| Memorial Health Partners Foundation, Inc | 8022919570 | 303 |
News Archive
Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF's medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS' refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
› Verified 2 days ago
| Entity Name | University Health System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790738763 PECOS PAC ID: 5294646378 Enrollment ID: O20031111000809 |
News Archive
Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF's medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS' refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
› Verified 2 days ago
| Entity Name | Memorial Health Partners Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922053545 PECOS PAC ID: 8022919570 Enrollment ID: O20040116000823 |
News Archive
Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF's medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS' refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chad E Paxson, DO 725 Glenwood Dr, Suite E-500, Chattanooga, TN 37404-1163 Ph: (423) 495-2635 | Dr Chad E Paxson, DO 725 Glenwood Dr, Suite E-500, Chattanooga, TN 37404-1163 Ph: (423) 495-2635 |
News Archive
Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF's medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS' refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
› Verified 2 days ago
Dr. Pamela Rani Sud, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 725 Glenwood Drive, Suite E-500, Chattanooga, TN 37404 Phone: 423-495-2635 Fax: 423-495-2638 | |
David Shved, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5179 Fax: 423-778-2108 | |
Megan J Coylewright, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-8258 | |
Dr. Charles Robert Bosshardt, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2515 Desales Ave Ste 206, Chattanooga, TN 37404 Phone: 423-698-8101 Fax: 423-698-3450 | |
Dr. Elise Helene Marshall, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 605 Glenwood Dr Ste 300, Chattanooga, TN 37404 Phone: 423-495-2690 Fax: 423-495-2698 | |
Dr. Joshua Warner Hornsby, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 979 E 3rd St Ste A-440, Chattanooga, TN 37403 Phone: 423-778-2867 Fax: 423-778-2866 | |
Dr. Donald Franklin Mackler, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste. W552, Chattanooga, TN 37404 Phone: 423-629-6258 Fax: 423-629-9531 |